Resmetirom
Resmetirom has been studied in 41 papers since 2024: 1 trial and 1 observational study in people, 2 in animals, 1 in cells, 34 reviews; 33 in the past year. It is an approved medicine. The newest paper, Nov 16, 2026: “Real‐World Initiation of Resmetirom and Recorded Incretin Exposure in the United States”.
12 new papers in 30 daysSee all 51 papers on resmetirom
At a glance
Independent labs found the same change in people. 6 independent labs in 5 countries; 14 trials, none about aging, 3 with no results posted.
“Low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and lipoprotein(a) [Lp(a)] were reduced irrespective of baseline statin use;”
1 of its findings points the other way.
- 6 independent labs in 5 countries
- 1 finding against
- 14 trials, none about aging, 3 with no results posted
- Funders: Madrigal Pharmaceuticals and others
- 5 of 17 findings with company ties
- 12 of 14 trials sponsored by its developers
- Human trial1
- Humans1
- Animals2
- Cells1
- In silico2
What did studies of resmetirom find?
21Studies of resmetirom measured 21 outcomes, among them liver fibrosis, LDL cholesterol and liver fibrosis.
Liver fibrosis
downin humans2no changein humans1RR 1.37–1.99
2 studies
Liver fibrosis
downin humans2no changein humans1RR 1.37–1.99
Resmetirom decreases liver fibrosis in humans (regardless of baseline statin use).
Human trialregardless of baseline statin useliver52 weeks
Resmetirom showed no clear effect on liver fibrosis in MASH patients without T2DM (RR = 1.37, 95% CI 0.83-2.25, p = 0.21).
Reviewin MASH patients without T2DM52-72 weeksn = 319
Resmetirom decreases liver fibrosis in MASH patients with T2DM (RR = 1.99, 95% CI 1.35-2.93, p = 0.0005).
Reviewin MASH patients with T2DM52-72 weeksn = 647
LDL cholesterol
downin humans2
2 studies
LDL cholesterol
downin humans2
Resmetirom decreases LDL cholesterol in humans with or without baseline statin use; placebo-corrected changes (80 mg and 100 mg, respectively: −12.0% and −18.7% on statins; −15.3% and −14.1% not on statins).
Human trialwith or without baseline statin use; placebo-corrected changes80 mg or 100 mg24 weeks
Resmetirom decreases LDL cholesterol in humans (-15.21% LDL cholesterol (95% CI -18.99 to -11.43)).
Reviewn = 1,996
Liver fibrosis
downin humans1downin reviews1
2 studies
Liver fibrosis
downin humans1downin reviews1
Resmetirom decreases liver fibrosis in humans.
Reviewliver52 weeks
Resmetirom decreases liver fibrosis.
Reviewin adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2), if locally approvedliver
Projected 10-year atherosclerotic cardiovascular disease risk
downin humans1
1 study
Projected 10-year atherosclerotic cardiovascular disease risk
downin humans1
Resmetirom decreases projected 10-year atherosclerotic cardiovascular disease risk in humans (Modeled using epidemiological frameworks, not observed clinical events) (Projected relative risk reductions: 2.3% Lp(a) model, 19.3% apoB model, 9.8% LDL-cholesterol model, and 11.8% combined model).
ReviewModeled using epidemiological frameworks, not observed clinical events10 years (modeled projection)
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Resmetirom decreases systolic blood pressure in humans (-3.08 mmHg systolic and -1.74 mmHg diastolic blood pressure).
Review
Hepatic and metabolic outcomes
upin humans1
1 study
Hepatic and metabolic outcomes
upin humans1
Resmetirom improves hepatic and metabolic outcomes in humans (metabolic dysfunction-associated steatotic liver disease and obesity).
Reviewmetabolic dysfunction-associated steatotic liver disease and obesityliver
Statin-related adverse events
no changein humans1
1 study
Statin-related adverse events
no changein humans1
Resmetirom showed no clear effect on statin-related adverse events in humans (baseline statin use).
Human trialbaseline statin use52 weeks
Liver fat
downin humans1
1 study
Liver fat
downin humans1
Resmetirom decreases liver fat in humans (regardless of baseline statin use).
Human trialregardless of baseline statin useliver52 weeks
MASH resolution
upin humans1
1 study
MASH resolution
upin humans1
Resmetirom increases MASH resolution in humans (regardless of baseline statin use).
Human trialregardless of baseline statin useliver52 weeks
Autophagy
upin mouse cells1
1 study
Autophagy
upin mouse cells1
Resmetirom activates autophagy in AML12 cells.
Cellsin AML12 cells
Aging and Western diet impair thyroid hormone signaling in mice
Aging cell
All 21Fewer
Has resmetirom been tested in people?
0 of 14 about agingYes: 1 trial and 1 observational study in people have been published, and 11 trials are registered.
Approved
Mar 14, 2024metabolic dysfunction-associated steatohepatitis, steatohepatitis, nonalcoholic steatohepatitis
Aug 18, 2025Non-alcoholic Fatty Liver Disease, metabolic dysfunction-associated steatohepatitis
Repurposing
Phase 3Completed3 trials
Phase 3Completed2 trials
Phase 2Recruiting1 trial
Phase 2Recruiting1 trial
Heterozygous familial hypercholesterolemia
Phase 2Results posted1 trial
Heart failure with preserved ejection fraction
Phase 1Recruiting1 trial
All 7Fewer
In trials
MASH metabolic dysfunction associated steatohepatitis
Phase 4Recruiting3 trials
Hyperlipidemias
Phase 3Completed2 trials
Thyroid Hormone Resistance Syndrome
Phase 3Completed2 trials
Drug safety
Phase 1Completed1 trial
Readouts due
- Mar 2027
- Oct 2027
- Nov 2027
Resmetirom in Patients With MASH and HFpEF
Phase 1Recruiting
- Nov 2027
Who is developing resmetirom?
2 companies: Madrigal Pharmaceuticals and Sagimet Biosciences.
Trial sponsors
Company8 trialsPhase 42,670 people
Company1 trialPhase 4165 people
Company1 trialPhase 140 people